Mn-loaded apoferritin: A highly sensitive MRI imaging probe for the detection and characterization of hepatocarcinoma lesions in a transgenic mouse model

Contrast Media and Molecular Imaging

Volumn 7, Issue 3, 2012, Pages 281-288

  Geninatti Crich, Simonetta ^a   Cutrin, Juan Carlos ^a,b   Lanzardo, Stefania ^a   Conti, Laura ^a   Kálmán, Ferenc K ^a,c   Szabó, Ibolya ^a   Lago, Néstor R ^d   Iolascon, Achille ^e   Aime, Silvio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Ferritin; Hepatocellular carcinoma; Manganese; Molecular imaging; MRI

Indexed keywords

APOFERRITIN; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; MANGANESE; MANGANESE APOFERRITIN COMPLEX; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; RECEPTOR PROTEIN; SCARA5 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; APOFERRITINS; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; CONTRAST MEDIA; HEPATOCYTES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MANGANESE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RATS; SCAVENGER RECEPTORS, CLASS A;

EID: 84860358385     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.492     Document Type: Article

References (32)

1. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010; 15: 14-22.
2. Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 2010; 15(suppl 4): 42-52.
3. Digumarthy SR, Sahani DV, Saini S. MRI in detection of hepatocellular carcinoma (HCC). Cancer Imag 2005; 5: 20-24.
4. Shimofusa R, Ueda T, Kishimoto T, Nakajima M, Yoshikawa M, Kondo F, Ito H. Magnetic resonance imaging of hepatocellular carcinoma: a pictorial review of novel insights into pathophysiological features revealed by magnetic resonance imaging. J Hepatobil Pancreat Sci 2010; 17: 583-589.
5. Edelman RR, Siegel JB, Singer A, Dupuis K, Longmaid HE. Dynamic MR imaging of the liver with Gd-DTPA: initial clinical results. Am J Roentgenol 1989; 153: 1213-1219.
6. Seale MK, Catalano OA, Saini S, Hahn PF, SahanI DV. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 2009; 29: 1725-1748.
7. Ito K. Hepatocellular carcinoma: conventional MRI findings including gadolinium-enhanced dynamic imaging. Eur J Radiol 2006; 58: 186-199.
8. Leonhardt M, Keiser M, Oswald S, Kühn J, Jia J, Grube M, Kroemer HK, Siegmund W, Weitschies W. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 2010; 38: 1024-1028.
9. Pascolo L, Cupelli F, Anelli PL, Lorusso V, Visigalli M, Uggeri F, Tiribelli C. Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun 1999; 257: 746-752.
10. Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, Taura K, Yasuchika K, Nitta T, Ikai I, Uemoto S. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-798.
11. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J 2011; 434: 365-381.
12. Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 2009; 1790: 589-599.
13. Li JY, Paragas N, Ned RM, Qiu A, Viltard M, Leete T, Drexler IR, Chen X, Sanna-Cherchi S, Mohammed F, Williams D, Lin CS, Schmidt-Ott KM, Andrews NC, Barasch J. Scara5 is a ferritin receptor mediating non-transferrin iron delivery. Dev Cell 2009; 16: 35-46.
14. Troadec MB, Ward DM, Kaplan J. A Tf-independent iron transport system required for organogenesis. Dev Cell 2009; 16: 3-4.
15. Huang J, Zheng DL, Qin FS, Cheng N, Chen H, Wan BB, Wang YP, Xiao HS, Han ZG. Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest 2010; 120: 223-241.
16. Kálmán FK, Geninatti-Crich S, Aime S. Reduction/dissolution of a beta-MnOOH nanophase in the ferritin cavity to yield a highly sensitive, biologically compatible magnetic resonance imaging agent. Angew Chem Int Edn Engl 2010; 49: 612-615.
17. Chisari FV, Pinkert CA, Milich DR, Filippi P, McLachlan A, Palmiter RD, Brinster RL. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985; 230: 1157-1160.
18. Barone M, Spano D, D'Apolito M, Centra M, Lasalandra C, Capasso M, Di Leo A, Volinia S, Arcelli D, Rosso N, Francavilla A, Tiribelli C, Iolascon A. Gene expression analysis in HBV transgenic mouse liver: a model to study early events related to hepatocarcinogenesis. Mol Med 2006; 12: 115-123.
19. Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990; 50: 3400-3407.
20. Pastor CM, Planchamp C, Pochon S, Lorusso V, Montet X, Mayer J, Terrier F, Vallee JP. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. Radiology 2003; 229: 119-125.
21. Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther 2010; 10: 507-519.
22. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010; 30(1): 17-25.
23. Aime S, Aime S, Delli Castelli D, Geninatti Crich S, Gianolio E, Terreno E. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications. Acc Chem Res 2009; 42: 822-831.
24. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006; 35: 512-523.
25. Geninatti Crich S, Bussolati B, Tei L, Grange C, Esposito G, Lanzardo S, Camussi G, Aime S. Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res 2006; 66: 9196-9201.
26. Fries PH, Belorizky E. Enhancement of the water proton relaxivity by trapping Gd3+ complexes in nanovesicles. J Chem Phys 2010; 133: 024504.
27. Sánchez P, Valero E, Gálvez N, Domínguez-Vera JM, Marinone M, Poletti G, Corti M, Lascialfari A. MRI relaxation properties of water-soluble apoferritin-encapsulated gadolinium oxide-hydroxide nanoparticles. Dalton Trans 2009; 5: 800-804.
28. Kim JH, Kim MJ, Park YN, Lee JT, Kim BR, Chung JB, Choi JS, Kim KS, Kim KW. Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics. Clin Radiol 2008; 63: 1195-1204.
29. Planchamp C, Montet X, Frossard JL, Quadri R, Stieger B, Meier PJ, Ivancevic MK, Vallée JP, Terrier F, Pastor CM. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol 2005; 40: 187-194.
30. Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, Iavarone M, Colombo M, Jang JJ, Yu E, Jin SY, Morenghi E, Park YN, Roncalli M. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009; 50: 746-754.
31. Bradford MMA. rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
32. Gardini G, Cabella C, Cravanzola C, Vargiu C, Belliardo S, Testore G, Solinas SP, Toninello A, Grillo MA, Colombatto S. Agmatine induces apoptosis in rat hepatocyte cultures. J Hepatol 2001; 35: 482-489.